Jazz sues FDA, HHS over rival narcolepsy drug approval
Jazz Pharmaceuticals is suing the FDA and HHS in federal court, asking a judge to block what it called an “unlawful” approval by federal regulators of a rival narcolepsy product.
Jazz filed a lawsuit against the agencies in US District Court for the District of Columbia Thursday, alleging the approval of Avadel Pharmaceuticals’ Lumryz, a rival product to its own narcolepsy drug, is unlawful due to protections on its own drug under the Orphan Drug Act (ODA).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.